Get the tools used by (smart)2 investors.
SP500 -5.8%DOW -5.4%FTSE 100 -4.9%NIKKEI -2.6%OIL -6.0%GOLD -2.3%
Sign In
WatchlistsIdeasScreenerData ExplorerChartsSaved Work

Capital Expenditures Forecast (FINBOX) for AstraZeneca PLC

Join now and get access to the full platform

Search for company or ETF

 

  0 results available. Select is focused ,type to refine list, press Down to open the menu,

AZNC.F: AstraZeneca PLC

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso...

136.64 USD
Price
– USD
Fair Value
–
Upside
120.64 - 175.00
52-week range
Create ChartCreate ModelAdd To Watchlist

Analysis

Fiscal Years
Trailing Twelve Months
Fiscal Halfs
Fiscal Quarters
Daily
Hide this widget

The following section summarizes insights on AstraZeneca PLC's Capital Expenditures Forecast (FINBOX):

Dec 2026Dec 2028Dec 2030Dec 2032Dec 20341.8 B2 B2.2 B2.4 B2.6 B2.8 B
Performance Summary
  • AstraZeneca's capital expenditures forecast for the next fiscal year is 2.215 billion
  • AstraZeneca's capital expenditures forecast is expected to average 2.266 billion over the next 5 fiscal years.
  • AstraZeneca's is expected to deliver median capital expenditures forecast of 2.22 billion over the next 5 fiscal years.

How does AstraZeneca PLC's Capital Expenditures Forecast (FINBOX) benchmark against competitors?

Hide this widget

We've identified the following companies as similar to AstraZeneca PLC because they operate in a related industry or sector. We also considered size, growth, and various financial metrics to narrow down the list to the ones listed below.

AstraZeneca PLC Capital Expenditures Forecast (FINBOX) Benchmarks
NameTickerCapital Expenditures Forecast (FINBOX)
HealthcareSECTOR:HLTH.GB500 K
HALEON PLCLSE:HLN342.8 M
Viatris Inc.LSE:0A5V390.3 M
H Lundbeck LLSE:0ND5577.7 M
Bristol-Myers Squibb CompanyLSE:0R1F1.16 B
Novartis AGLSE:0QLR1.21 B
GSK plcLSE:GSK1.449 B
AstraZeneca PLCOTCPK:AZNC.F2.215 B
Pfizer Inc.LSE:0Q1N2.799 B
Merck & Co IncLSE:0QAH3.397 B
Johnson & JohnsonLSE:0R343.9 B
Eli Lilly and CoLSE:0Q1G4.209 B

Metric Usage: Capital Expenditures Forecast

Hide this widget
capex_proj
Slug
number
Datatype
text
Format
current
Default Period
FY, Q
Periods Supported
Free
Plan

To view the full list of supported financial metrics please see Complete Metrics Listing.

Similar Metrics

Hide this widget

Metrics similar to Capital Expenditures Forecast (FINBOX) in the forecast category include:

View Full List

Search for metric or datapoint

Capital Expenditures Forecast

Projected capital expenditures.

Definition of Capital Expenditures Forecast (FINBOX)

Hide this widget
Projected capital expenditures.

Sector Benchmark Analysis

Sector
Industry Group
Industry
Hide this widget
0 K200 M400 M715.4 M05001,0001,5002,000

The chart above depicts the distribution of capital expenditures forecast (finbox) for companies operating in the Healthcare sector in the Developed economic region. Over 2,530 companies were considered in this analysis, and 2,485 had meaningful values. The average capital expenditures forecast (finbox) of companies in the sector is 22.951 M with a standard deviation of 79.986 M.

AstraZeneca PLC's Capital Expenditures Forecast (FINBOX) of 2.215 B is significantly outside the interquartile range and is excluded from the distribution. The following table provides additional summary stats:

Capital Expenditures Forecast (FINBOX) In The Healthcare Sector
Economic Risk RegionDeveloped
Total Constituents2,536
Included Constituents2,485
Min0 K
Max712.5 M
Median912.125 K
Mean22.951 M
Standard Deviation79.986 M

You can find companies with similar capital expenditures forecast (finbox) using this stock screener.

All rights reserved. Terms Of Use